The most common cause of recurrent trichomoniasis is reinfection from an untreated sexual partner, not a failure of the original treatment. Up to 70% of male sexual partners of infected women carry the parasite, often without symptoms, creating a cycle where the infection passes back and forth. Beyond reinfection, drug resistance, vaginal microbiome disruption, and incomplete treatment all play a role.
Untreated Partners Are the Top Cause
Trichomoniasis is caused by a single-celled parasite called Trichomonas vaginalis, and it spreads through sexual contact. The biggest driver of recurrence is straightforward: your partner still has it. Most men with trichomoniasis have no symptoms at all, so they have no reason to suspect they’re infected. When only one partner gets treated, the untreated partner reintroduces the parasite as soon as sexual activity resumes.
This is why the CDC recommends that all sexual partners be treated at the same time, even without a positive test. It’s also why retesting is recommended about three months after treatment. That three-month window catches both reinfections from partners and cases where the initial treatment didn’t fully clear the parasite.
Drug Resistance in 4% to 10% of Cases
The only class of medications that works against trichomoniasis is the nitroimidazole family, which includes the two most commonly prescribed options. There is no backup drug class if these don’t work. Resistance to these medications occurs in roughly 4% to 10% of vaginal trichomoniasis cases, according to CDC estimates. For people in that group, a standard single-dose treatment may reduce the parasite load without fully eliminating it, leading to a positive test weeks later.
When resistance is suspected, doctors typically move to a longer, higher-dose regimen rather than simply repeating the same prescription. A newer single-dose alternative has shown a microbiologic cure rate of about 92% in clinical trials and performed comparably to multi-dose regimens in available studies. For persistent infections, a multi-day course of this medication achieved a combined cure rate of 97% in one study. These options give clinicians more flexibility, but the fundamental limitation remains: there’s only one drug class to work with.
Your Vaginal Microbiome Affects Susceptibility
The bacterial environment inside the vagina plays a larger role in trichomoniasis recurrence than most people realize. A healthy vaginal microbiome is dominated by Lactobacillus bacteria, which produce lactic acid and keep the pH low. That acidic environment makes it harder for the trichomoniasis parasite to establish itself. One species in particular, Lactobacillus crispatus, is associated with the strongest protection against infections.
Not all Lactobacillus species offer the same defense. A microbiome dominated by Lactobacillus iners, for example, provides weaker protection and is more commonly found in women with bacterial vaginosis (BV). Research shows that L. iners can survive alongside the trichomoniasis parasite by adapting to the stress it creates, rather than suppressing it effectively.
BV itself is a major risk factor. When the vaginal microbiome shifts away from Lactobacillus dominance and toward a mix of anaerobic bacteria, the protective acid barrier weakens. The bacteria associated with BV collectively increase the permeability of vaginal tissue, compromise its structural integrity, and trigger inflammatory signals. This creates an environment where the trichomoniasis parasite can take hold more easily. About half of BV cases produce no noticeable symptoms, so you may not know your microbiome is disrupted. If you keep getting trichomoniasis despite proper treatment and partner management, an underlying microbiome imbalance could be part of the picture.
Retesting Too Early Can Mislead
Sometimes what looks like recurrence is actually a testing issue. The most sensitive diagnostic tests use nucleic acid amplification (NAAT), which detects genetic material from the parasite. These tests are highly accurate, but they can pick up residual DNA from dead parasites for a period after successful treatment. If you retest too soon, a positive result may reflect the previous infection rather than a new or persistent one.
The optimal timing for a follow-up test depends on how you were treated. If you took a multi-day course, retesting is most accurate at three weeks or later. For a single-dose treatment, four weeks is the recommended minimum. Testing before these windows risks a false positive that could lead to unnecessary retreatment and the perception that the infection keeps coming back when it was actually cured.
Why Recurrence Matters Beyond Discomfort
Recurrent trichomoniasis isn’t just a nuisance. The parasite causes inflammation in the genital tract, and that inflammation has real consequences. Trichomoniasis increases the risk of acquiring HIV by 1.5 to 3 times, because the inflammatory response damages the mucosal barrier that normally helps block viral entry. Each episode of reinfection renews that vulnerability.
The infection is also linked to complications during pregnancy and increased susceptibility to other sexually transmitted infections. Breaking the cycle of recurrence, whether through simultaneous partner treatment, addressing microbiome health, or switching to a more effective medication regimen, reduces these downstream risks significantly.
Steps That Actually Break the Cycle
If you’ve had trichomoniasis more than once, the first question to address honestly is whether all of your sexual partners were treated before you resumed contact. This single factor accounts for the majority of recurrences. Partners should be treated at the same time you are, not after your results come back, and both of you should wait to have sex until treatment is complete and symptoms have resolved.
If partner treatment has been thorough and you’re still testing positive, the issue is more likely drug resistance or a microbiome environment that leaves you vulnerable to reinfection. Your doctor can request susceptibility testing to check whether the parasite responds normally to standard medications. If resistance is confirmed, a longer or higher-dose treatment plan is the next step. Addressing concurrent BV, if present, may also help restore the vaginal environment to one that’s more resistant to colonization.
Finally, make sure your follow-up test is timed correctly. Retesting at three to four weeks post-treatment gives you the most reliable answer about whether the infection has truly cleared, without the confusion of residual parasite DNA triggering a false alarm.